Home » News

News

Summary of ECCO Consensus Guidelines 2017 on Ulcerative Colitis

Medical Management of Active UC1 The treatment strategy for ulcerative colitis  (UC) is mainly based on the severity, distribution (proctitis, left-sided, extensive) and pattern of disease. The latter includes relapse frequency, disease course, response to previous medications, side effects of medication, and extra-intestinal manifestations. Age at onset, and disease duration are also important factors. It is important to distinguish patients ...

Tremfya ▼ Receives Approval for Treatment of Moderate to Severe Plaque Psoriasis

Janssen is pleased to announce that Tremfya (guselkumab) is now available in Ireland for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy.1 Guselkumab, a human IgG1l monoclonal antibody, is the first biologic that selectively blocks interleukin (IL)-23, a key driver of the immune inflammatory response in psoriasis. IL-23 affects the differentiation, expansion, ...

Hay Fever Policy (Glucocorticoid Injections)

Therapeutic Use Exemption (TUE) Committee Policy on Glucocorticoid Injections for Hay Fever Methylprednisolone (Depo-Medrone) and Triamcinolone (Kenalog*) administered by intramuscular injection as treatment for hay fever are prohibited in sport and therefore their use requires the athlete and their physician to strictly adhere to the TUE Policy. The TUE Policy is available at www.sportireland.ie/Anti-Doping/Athlete-Zone/Therapeutic-Use-Exemptions-/ Athletes included in their International Federation ...

Valproate (Epilim): New contraindications, strengthened warnings and measures to prevent exposure during pregnancy

Valproate-containing medicines (licensed in Ireland as Epilim) are now contraindicated in women of childbearing potential unless the terms of a special pregnancy prevention programme are followed. Valproate should not be used in female children and women of childbearing potential unless other treatments are ineffective or not tolerated. In 2014 the warnings and restrictions regarding the use of valproate in women ...

New Products 2018

MAY Symtuza ▼ (darunavir, cobicistat, emtricitabine, tenofovir alafenamide) Tremfya ▼(guselkumab) APRIL Accu-Chek Fastclix (diagnostic) Accu-Chek Mobile (diagnostic) Bavencio▼ (avelumab) Fortisip Compact Protein (nutrition) Peyona (caffeine citrate) Vosevi▼ (sofosbuvir, velpatasvir, voxilaprevir) MARCH Kyntheum ▼ (brodalumab) Humira 80mg/0.8ml (adalimumab) FEBRUARY Keytruda 25mg/ml ▼ (pembrolizumab) Noqturina (desmopressin) JANUARY Altrashot (nutrition) Duloxetine Rowa (duloxetine) Entresto ▼(sacubitril, valsartan) Foodlink Complete (nutrition) Foodlink Complete with Fibre (nutrition) Stérimar Cold ...

Capoten, Capozide, Nalorex and Sotacor Discontinued

Bristol-Myers Squibb would like to inform you that the following products were discontinued as of 31st March 2018 in Ireland for commercial reasons: Capoten (captopril) 25mg and 50mg tablets; Capozide (captopril/HCTZ) 50/25mg tablets; Nalorex (naltrexone) 50mg tablets; Sotacor (sotalol) 80mg tablets. For further information, please contact the BMS Medical Information department at 1800 749 749 or at medical.information@bms.com

Lung Cancer – Epidemiology, Guideline, Treatment

EPIDEMIOLOGY The 2017 report of the National Cancer Registry summarised cancer incidence, mortality and survival in Ireland for the period 1994-2015, and provided projected estimates for incidence for the most recent three-year period, 2015-2017. For all invasive cancers excluding non-melanoma skin cancers, lung cancer was the 3rd most common cancer diagnosed in males (11.8%), and the 2nd most common cancer ...

Breast Cancer – Epidemiology, Guideline, Treatment

EPIDEMIOLOGY The National Cancer Registry 2017 report summarised cancer incidence, mortality and survival in Ireland during 1994-2015, and provided estimated incidence for the period 2015-2017. Breast cancer was the most commonly diagnosed invasive cancer in women (30.1%) from 2015-2017 (estimated incidence), excluding non-melanoma skin cancers. On average, 27 men were diagnosed with breast cancer in Ireland every year during this ...

Prostate Cancer – Epidemiology, Guideline, Treatment

EPIDEMIOLOGY The National Cancer Registry 2017 report summarised cancer incidence, mortality and survival in Ireland during 1994-2015, and provided estimated incidence for the period 2015-2017. Prostate cancer was the most commonly diagnosed invasive cancer in men (29.2%) from 2015-2017 (estimated annual average incidence), excluding non-melanoma skin cancers. Deaths from prostate cancer accounted for 11.2% of all male cancer deaths during ...

Xofigo (Radium-223 Dichloride) – Contraindicated in Combination with Abiraterone Acetate (Zytiga) and Prednisone/Prednisolone

The European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) has recommended a contraindication regarding use of Xofigo in combination with abiraterone acetate (Zytiga) and prednisone/prednisolone. This recommendation follows the review of preliminary data from an ongoing clinical trial which shows an increased risk of death and fractures. Pending conclusion of the review and to allow a thorough assessment of ...